Phibro Animal Health Corp (NASDAQ: PAHC) is an animal health company that develops, manufactures, and sells products for livestock and other animals. Revenue comes from transactional product sales across two reported segments: Animal Health and a separate segment, with Animal Health being the primary business. The company competes in a highly fragmented global animal health market against large and small regional competitors, some with greater financial and R&D resources, as stated in the FY2025 10-K filed August 27, 2025. PAHC manufactures across owned facilities in the United States, Brazil, Argentina, Ireland, and Israel, among other locations. Key products include medicated feed additives (MFAs), including antibacterials such as virginiamycin, oxytetracycline, chlortetracycline, and the branded product Mecadox (carbadox). As of June 30, 2025, the company carried $59.6 million in goodwill and $36.5 million in net identifiable intangible assets. The company operates under a 2024 Credit Facilities agreement that carries restrictive debt covenants.

Revenue model

Transactional product sales of animal health products, primarily medicated feed additives and antibacterials sold to livestock producers and related customers.

Products and services

Medicated feed additives (MFAs), antibacterials including virginiamycin, oxytetracycline, neomycin, streptomycin, tiamulin, chlortetracycline, sulfamethazine, and the branded product Mecadox (carbadox).

Customers and end markets

Livestock producers and the broader food animal production industry, including cattle, swine, and poultry end markets. Demand is tied to the health and scale of the global livestock industry.

Value-chain role

Manufacturer and seller of animal health products. Owns manufacturing, research, and administrative facilities across multiple countries. Relies on third-party IT and cloud infrastructure vendors for operational systems.

Geographic exposure

Manufacturing and operations in the United States (Sarasota FL, Chillicothe IL, Mendon IL, St. Paul MN, Omaha NE), Brazil (Braganca Paulista, Guarulhos, Heliópolis), Argentina (Buenos Aires), Ireland (Sligo), and Israel (Beit Shemesh, Neot Hovav, Petach Tikva), as disclosed in the FY2025 10-K.

Source: SEC 10-K, filed 2025-08-27

Industry: Pharmaceutical Preparations Peers: ANI Pharmaceuticals Inc Atea Pharmaceuticals Inc BIODELIVERY SCIENCES INTERNATIONAL INC Tvardi Therapeutics Inc Collegium Pharmaceutical Inc Edgewise Therapeutics Inc Nektar Therapeutics Johnson & Johnson Tricida, Inc.